Back to articles

Ray of Hope: FDA Greenlights Crucial Dose for Pancreatic Cancer Breakthrough Drug

Leila Cohen•Jun 13, 2025
An artist's rendition of an immune cell (T-cell) being activated by mitazalimab to attack a pancreatic cancer cell, with a subtle glow of hope or light emanating from the interaction.
  • Major Milestone: Alligator Bioscience's mitazalimab receives FDA backing for its Phase 3 dose, a critical step against aggressive pancreatic cancer.
  • Hope for Patients: Pancreatic cancer (mPDAC) has grim survival rates; mitazalimab offers a novel immunotherapy approach with "unprecedented survival data" in earlier trials.
  • Path Forward: With FDA support, Alligator Bioscience actively seeks partners to launch the pivotal Phase 3 trial, bringing this promising treatment closer to patients.

In the relentless battle against one of the most formidable and lethal adversaries, metastatic pancreatic ductal adenocarcinoma (mPDAC), a significant beacon of hope has emerged. Alligator Bioscience today announced a pivotal victory: the U.S. Food and Drug Administration (FDA) has endorsed the selected 900 µg/kg dose for mitazalimab's upcoming Phase 3 trial3. This isn't just a regulatory nod; it's a crucial affirmation in the quest to bring a potentially life-altering therapy to patients facing a devastating diagnosis where options are tragically scarce8.

Mitazalimab, a sophisticated CD40 agonist antibody, works by awakening the body's own immune system, specifically priming tumor-slaying T cells to recognize and obliterate cancer cells1, 6. This approach aims to reverse the tumor's insidious ability to suppress immune defenses. The drug has already shown breathtaking promise, with its Phase 2 OPTIMIZE-1 trial revealing unprecedented 24-month survival data in first-line mPDAC patients when combined with chemotherapy5, 8.

"We are very pleased with the FDA's timely and constructive response," stated Søren Bregenholt, CEO of Alligator Bioscience. "This marks an important step forward as we finalize our Phase 3 program for mitazalimab in one of the most aggressive and underserved cancers."

With this vital FDA support, Alligator Bioscience is now urgently pursuing partnerships to propel mitazalimab into its decisive Phase 3 trials3, 4. The fight against pancreatic cancer is arduous, but this development signals a powerful new weapon may soon join the arsenal, offering a desperately needed chance for patients worldwide.

References

  1. alligatorbioscience.se
  2. alligatorbioscience.se
  3. www.biospace.com
  4. alligatorbioscience.se
  5. alligatorbioscience.se
  6. www.aacrmeetingnews.org
  7. alligatorbioscience.se
  8. alligatorbioscience.se

Stay Updated!

Get the latest biotech and pharma news delivered to your inbox.